Nucletron B.V. (Nucletron), a Netherlands-based radiation oncology company, has reported net sales of EUR112.4 million ($165 million) for the year-end 2008. EBITDA in 2008 ended at an all time high (in constant currencies) of EUR17 million. Despite challenging global economic conditions, Nucletron surpassed projections in 2008 due in large part to a renewed focus on brachytherapy treatment and an expanding product offering in external beam treatment planning software solutions.
Subscribe to our email newsletter
Among the several advancements announced in 2008 was the introduction on Oncentra Brachy, a new volume-based treatment planning solution that optimizes cancer treatment planning with brachytherapy. Additionally, Oncentra RT Viewer received clearance in 2008. Oncentra RT Viewer enables clinicians to review radiotherapy plans generated with a wide variety of DICOM-compliant treatment planning systems in a Windows (PC) environment.
“In the second half of 2008, we improved our focus on innovation and marketing efforts, while strengthening our management team. Given our many upcoming product releases in the months to come, we are on track to achieve our 2009 goals as planned,” said Jos Lamers, chief executive officer of Nucletron.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.